Literature DB >> 1181667

The effect of somatostatin on the response of GLI to the intraduodenal administration of glucose, protein, and fat.

H Sakurai, R E Dobbs, R H Unger.   

Abstract

The effects of somatostatin on GLI release during the absorption of intraduodenally administered glucose, casein hydrolysate and longchain triglycerides were studied in conscious dogs. Whereas, after an intraduodenal glucose load, GLI rose promptly in saline-infused control experiments to a peak of 5 ng/ml (SEM +/- 4) in 60 minutes, significantly lower values were observed during somatostatin infusion (P less than 0.025 -- 0.05). A similar reduction in the magnitude of the GLI response to intraduodenally administered casein hydrolysate (P less than 0.05) and fat (p less than 0.05) was observed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1181667     DOI: 10.1007/bf00429911

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

2.  Somatostatin: hypothalamic inhibitor of the endocrine pancreas.

Authors:  D J Koerker; W Ruch; E Chideckel; J Palmer; C J Goodner; J Ensinck; C C Gale
Journal:  Science       Date:  1974-04-26       Impact factor: 47.728

3.  Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics.

Authors:  J E Gerich; M Lorenzi; V Schneider; C W Kwan; J H Karam; R Guillemin; P H Forsham
Journal:  Diabetes       Date:  1974-11       Impact factor: 9.461

4.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors:  C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

5.  Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone.

Authors:  S R Bloom; C H Mortimer; M O Thorner; G M Besser; R Hall; A Gomez-Pan; V M Roy; R C Russell; D H Coy; A J Kastin; A V Schally
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

6.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

7.  Acute suppression of insulin and glucose levels by synthetic somatostatin in normal human subjects.

Authors:  G W DeVane; T M Siler; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

8.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

9.  [Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecystokinin-pancreozymin administration (author's transl)].

Authors:  W Creutzfeldt; P G Lankisch; U R Fölsch
Journal:  Dtsch Med Wochenschr       Date:  1975-05-16       Impact factor: 0.628

10.  Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs.

Authors:  H Sakurai; R Dobbs; R H Unger
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more
  8 in total

Review 1.  Somatostatin--both hormone and neurotransmitter?

Authors:  R Luft; S Efendić; T Hökfelt
Journal:  Diabetologia       Date:  1978-01-14       Impact factor: 10.122

2.  Effect of food ingestion on intestinal glucagon-like immunoreactivity (GLI) secretion in normal and gastrectomized subjects.

Authors:  J Marco; J A Hedo; M L Villanueva; C Calle; A Corujedo; J M Segovia
Journal:  Diabetologia       Date:  1977-04       Impact factor: 10.122

Review 3.  The milieu interieur and the islets of Langerhans.

Authors:  R H Unger
Journal:  Diabetologia       Date:  1981       Impact factor: 10.122

Review 4.  Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.

Authors:  Claire M Issa; Sami T Azar
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

5.  Somatostatin and the intestinal transport of glucose and other nutrients in the anaesthetised rat.

Authors:  C Daumerie; J C Henquin
Journal:  Gut       Date:  1982-02       Impact factor: 23.059

6.  Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide.

Authors:  E Ipp; R E Dobbs; A Arimura; W Vale; V Harris; R H Unger
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

7.  Effects of somatostatin on gastric acid secretion and on lipid and carbohydrate metabolism in the rat.

Authors:  W G Linscheer; K L Raheja
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

8.  Does somatostatin in the gut inhibit the GLI release locally?

Authors:  S Ito; M Hayashi; A Shibata; Y Matsubara
Journal:  Acta Diabetol Lat       Date:  1980 Jan-Mar
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.